The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on May 23, 2017. This approval was for an efficacy supplement, indicating an expansion of its approved uses based on new clinical data. The application was submitted by Merck Sharp Dohme.
What this means
This supplemental approval for Keytruda (pembrolizumab) signifies that the FDA has recognized new evidence of efficacy for the drug, based on data submitted by sponsor Merck Sharp Dohme. While the specific indication or patient population for this efficacy supplement is not detailed in the available information, such approvals are critical regulatory milestones. They typically lead to an expanded label for the drug, allowing healthcare providers to prescribe pembrolizumab for additional conditions or in new treatment settings where its benefits have been demonstrated. This expansion broadens the therapeutic options available to patients who may benefit from Keytruda, an important immunotherapy.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 125514 S-14 for Keytruda (pembrolizumab) was recorded on May 23, 2017, and is accessible via accessdata.fda.gov.